Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management

Current Treatment Options in Cardiovascular Medicine
Katie M Murphy, Julie L Rosenthal

Abstract

The therapeutic heart failure armamentarium has evolved from drugs to transplantation to devices through further understanding of its complex pathophysiology and pathogenesis. Current medications capitalize on our evolving understanding of the sympathetic and renin-angiotensin-aldosterone systems that subsequently promote both beneficial and maladaptive responses that ultimately yield a decrease in cardiac function. Despite these advancements, the prevalence of heart failure continues to rise and carries a significant burden on our patients and health care system. This presents a clinical dilemma on how best to care for a growing, complex, and heterogeneous cohort. Ideal treatments should decrease morbidity and mortality while providing an improvement in quality of life and functional capacity. New interventions will continue to become incorporated into everyday practice, but awareness and prevention should remain the mainstay followed by optimization of guideline-directed therapies. It is equally important to individually tailor our therapeutic approach. While strategies to treat heart failure with reduced ejection fraction continue to advance, our understanding of how best to treat specific etiologies remain in question. This...Continue Reading

References

Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Apr 2, 2003·The New England Journal of Medicine·Bertram PittUNKNOWN Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators
Oct 13, 2005·European Heart Journal·Stuart J PocockChristopher B Granger
Apr 28, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Dario DiFrancesco
Jul 24, 2007·American Heart Journal·Soko SetoguchiSebastian Schneeweiss
Jan 26, 2008·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Irina Savelieva, A John Camm
Apr 10, 2009·Kidney International·George L BakrisErnest M Wright
Aug 6, 2009·Diabetologia·UNKNOWN Control GroupM Woodward
May 1, 2008·Circulation. Heart Failure·Arnold M Katz
Feb 20, 2010·Journal of the American Society of Nephrology : JASN·Richard H SternsSreedevi Chennupati
Nov 16, 2010·The New England Journal of Medicine·Faiez ZannadUNKNOWN EMPHASIS-HF Study Group
Feb 15, 2011·Lancet·William T AbrahamUNKNOWN CHAMPION Trial Study Group
May 12, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Michael BöhmLuigi Tavazzi
Nov 13, 2012·Lancet·John R TeerlinkUNKNOWN RELAXin in Acute Heart Failure (RELAX-AHF) Investigators
Jan 16, 2013·Nature Reviews. Cardiology·Chim C Lang, Allan D Struthers
Jul 11, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tim HeiseKlaus Dugi
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Sep 2, 2014·The New England Journal of Medicine·Kim FoxUNKNOWN SIGNIFY Investigators
Nov 18, 2014·JAMA : the Journal of the American Medical Association·Mikhail KosiborodBhupinder Singh
Nov 22, 2014·The New England Journal of Medicine·Matthew R WeirUNKNOWN OPAL-HK Investigators
Mar 15, 2015·Journal of the American College of Cardiology·Eugene Braunwald
Jul 15, 2015·JAMA : the Journal of the American Medical Association·George L BakrisUNKNOWN AMETHYST-DN Investigators
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Nov 20, 2015·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Cheryl A Thompson
Dec 18, 2015·Circulation·UNKNOWN Writing Group MembersUNKNOWN Stroke Statistics Subcommittee
Jan 29, 2016·European Heart Journal·David FitchettUNKNOWN EMPA-REG OUTCOME® trial investigators
Mar 25, 2016·The Annals of Pharmacotherapy·Jared A Schaefer, Mark A Gales

❮ Previous
Next ❯

Citations

Mar 16, 2018·Current Treatment Options in Cardiovascular Medicine·Paulino Alvarez, Alexandros Briasoulis

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Director : Official Publication of the National Association of Directors of Nursing Administration in Long Term Care
Laura Gaulden
© 2022 Meta ULC. All rights reserved